Zacks Investment Research
24 Jun 2026, 17:45 UTC · 2h ago
Is Neurocrine (NBIX) a Solid Growth Stock? 3 Reasons to Think "Yes"
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Zacks Investment Research
24 Jun 2026, 17:45 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
2 claims · each scored for market impact
Neurocrine Biosciences (NBIX) is projected to achieve EPS growth of 48.3% this year, significantly exceeding the industry average of 17.3%. — Strong earnings growth projections relative to peers typically drive positive price action for individual stocks.
+0.60Neurocrine Biosciences maintains a sales-to-total-assets (S/TA) ratio of 0.7, which is higher than the industry average of 0.48. — Higher asset efficiency indicates better operational management, though it is a secondary driver compared to earnings growth.
+0.30Which stocks this story touches
The company is explicitly recommended as a great growth pick with a top Zacks Rank and projected earnings growth crushing the industry average.
Continue reading
6 related stories
Search tags
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Zacks Investment Research
2h ago
